OBJECTIVE: To investigate the growth and pubertal attainment of boys with attention deficit hyperactivity disorder (ADHD) on stimulant medication. DESIGN, SETTING AND PARTICIPANTS: Longitudinal study of boys aged 12.00-15.99 years at recruitment in 2005-2011, with stimulant-treated ADHD for at least 3 years, attending three paediatric practices (subjects), compared with longitudinal data from 174 boys from the Nepean longitudinal study (controls). MAIN OUTCOME MEASURES: Subjects' growth parameters before treatment were compared with controls aged 7 or 8 years; growth parameters and longitudinal changes on treatment to ages 12.00-13.99 and 14.00-15.99 years were compared with controls reviewed at 13 and 15 years of age, respectively. The subjects' pubertal staging and height velocity were related to their treatment history. RESULTS: Sixty-five subjects were recruited; mean duration of treatment was 6.3 ± 1.9 years. At baseline, their growth parameters were not significantly different from those of the controls after adjusting for age. Compared with the controls, after adjusting for current age and baseline growth parameter z score, subjects aged 12.00-13.99 years had significantly lower weight and body mass index (P < 0.01), and those aged 14.00-15.99 years had significantly lower height and weight (P < 0.05). At 12.00-13.99 years of age, the subjects were comparable to the controls in their pubertal development adjusted for age, but those aged 14.00-15.99 years reported significant delay (mean Tanner stage, 3.6 for subjects v 4.0 for controls; P < 0.05). The dose of medication was inversely correlated with the height velocity from baseline to 14.00-15.99 years of age (P < 0.05). CONCLUSIONS: Prolonged treatment (more than 3 years) with stimulant medication was associated with a slower rate of physical development during puberty. To maintain adequate height velocity during puberty, we recommend keeping the dose as low as possible.
OBJECTIVE: To investigate the growth and pubertal attainment of boys with attention deficit hyperactivity disorder (ADHD) on stimulant medication. DESIGN, SETTING AND PARTICIPANTS: Longitudinal study of boys aged 12.00-15.99 years at recruitment in 2005-2011, with stimulant-treated ADHD for at least 3 years, attending three paediatric practices (subjects), compared with longitudinal data from 174 boys from the Nepean longitudinal study (controls). MAIN OUTCOME MEASURES: Subjects' growth parameters before treatment were compared with controls aged 7 or 8 years; growth parameters and longitudinal changes on treatment to ages 12.00-13.99 and 14.00-15.99 years were compared with controls reviewed at 13 and 15 years of age, respectively. The subjects' pubertal staging and height velocity were related to their treatment history. RESULTS: Sixty-five subjects were recruited; mean duration of treatment was 6.3 ± 1.9 years. At baseline, their growth parameters were not significantly different from those of the controls after adjusting for age. Compared with the controls, after adjusting for current age and baseline growth parameter z score, subjects aged 12.00-13.99 years had significantly lower weight and body mass index (P < 0.01), and those aged 14.00-15.99 years had significantly lower height and weight (P < 0.05). At 12.00-13.99 years of age, the subjects were comparable to the controls in their pubertal development adjusted for age, but those aged 14.00-15.99 years reported significant delay (mean Tanner stage, 3.6 for subjects v 4.0 for controls; P < 0.05). The dose of medication was inversely correlated with the height velocity from baseline to 14.00-15.99 years of age (P < 0.05). CONCLUSIONS: Prolonged treatment (more than 3 years) with stimulant medication was associated with a slower rate of physical development during puberty. To maintain adequate height velocity during puberty, we recommend keeping the dose as low as possible.
Authors: Laurence L Greenhill; James M Swanson; Lily Hechtman; James Waxmonsky; L Eugene Arnold; Brooke S G Molina; Stephen P Hinshaw; Peter S Jensen; Howard B Abikoff; Timothy Wigal; Annamarie Stehli; Andrea Howard; Michael Hermanussen; Tomasz Hanć Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-08-15 Impact factor: 8.829
Authors: Elizabeth B Harstad; Amy L Weaver; Slavica K Katusic; Robert C Colligan; Seema Kumar; Eugenia Chan; Robert G Voigt; William J Barbaresi Journal: Pediatrics Date: 2014-09-01 Impact factor: 7.124
Authors: Joel T Nigg; Jeanette M Johnstone; Erica D Musser; Hilary Galloway Long; Michael T Willoughby; Jackilen Shannon Journal: Clin Psychol Rev Date: 2015-12-02
Authors: James M Swanson; L Eugene Arnold; Brooke S G Molina; Margaret H Sibley; Lily T Hechtman; Stephen P Hinshaw; Howard B Abikoff; Annamarie Stehli; Elizabeth B Owens; John T Mitchell; Quyen Nichols; Andrea Howard; Laurence L Greenhill; Betsy Hoza; Jeffrey H Newcorn; Peter S Jensen; Benedetto Vitiello; Timothy Wigal; Jeffery N Epstein; Leanne Tamm; Kimberly D Lakes; James Waxmonsky; Marc Lerner; Joy Etcovitch; Desiree W Murray; Maximilian Muenke; Maria T Acosta; Mauricio Arcos-Burgos; William E Pelham; Helena C Kraemer Journal: J Child Psychol Psychiatry Date: 2017-03-10 Impact factor: 8.982
Authors: Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud Journal: Cochrane Database Syst Rev Date: 2018-05-09